| Literature DB >> 30092052 |
Treya M Long1, Shoshana R Rath2,3, Karen E Wallman1, Erin K Howie4, Leon M Straker4, Andrew Bullock5, Thomas S Walwyn3,6, Nicholas G Gottardo3,6,7, Catherine H Cole3,6,7,8, Catherine S Choong2,3, Louise H Naylor1.
Abstract
Adolescent and young adult (AYA) survivors of pediatric oncology related cerebral insult are vulnerable to numerous treatment-induced deficits that significantly enhance cardiovascular disease risk. Regular exercise improves endothelial function, fitness, body composition and musculoskeletal function which may reduce predisposition for cardiovascular disease. Here we assessed the feasibility and effectiveness of a 24-week exercise intervention on cardiovascular, physical and metabolic outcomes in this population. Thirteen survivors (6 male, 7 female; median age 19 y (range 16-23 y) were recruited to participate in a 48-week study consisting of a 24-week control period (regular care) followed by a 24-week exercise intervention. Outcome measures were collected at entry (week 0) and following regular care (24-week) and exercise (48-week). Assessed variables included endothelial function (flow mediated dilation, FMD), blood pressure, heart rate (HR), aerobic capacity, anthropometry, body composition, muscular strength (3 repetition maximum testing), muscular endurance (repetitions/min) and physical activity levels (accelerometry). Compared to baseline, delta diameter (p = 0.008) and FMD (p = 0.029) of the brachial artery increased following exercise. Bicep-curl strength also increased following exercise compared to baseline (p = 0.019), while submaximal (6 min mark) measures of ventilation (p = 0.012), rating of perceived exertion (p = 0.012), HR (p = 0.001), absolute (p = 0.000) and relative (p = 0.000) aerobic capacity decreased. Breaks in sedentary time increased (p = 0.043) following exercise compared to regular care. Although the sample was small and heterogeneous, this study demonstrates that exercise is achievable and has positive effects on vascular function, submaximal fitness, local strength and physical activity in a population of AYA survivors of pediatric oncology related cerebral insult.Entities:
Mesh:
Year: 2018 PMID: 30092052 PMCID: PMC6084859 DOI: 10.1371/journal.pone.0201449
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Participant characteristics.
| Survivors | ||
|---|---|---|
| No. | % | |
| Underlying Diagnosis | ||
| Brain Tumor | 9 | 69.23 |
| Tumor Type | ||
| Craniopharyngioma | 1 | 7.69 |
| Glioma | 7 | 53.85 |
| Medulloblastoma | 1 | 7.69 |
| Tumor Location | ||
| Brain Stem | 1 | 7.69 |
| Frontal Lobe | 2 | 15.39 |
| Optic Pathway | 1 | 7.69 |
| Posterior Fossa | 2 | 15.39 |
| Subependymal Zone | 1 | 7.69 |
| Temporal Lobe | 2 | 15.39 |
| Leukemia | 3 | 23.08 |
| ALL | 3 | 23.08 |
| Other | 1 | 7.69 |
| Undifferentiated rhabdomyosarcoma of the right petrous temporal bone | 1 | 7.69 |
| Treatment | ||
| Surgery | 5 | 38.46 |
| Surgery & XRT | 1 | 7.69 |
| Chemotherapy & XRT | 1 | 7.69 |
| Surgery, Chemotherapy & XRT | 4 | 30.77 |
| Chemotherapy, XRT & HSCT | 2 | 15.39 |
| Treatment Details | ||
| XRT | 8 | 61.54 |
| Dosage | ||
| 6–24 Gy | 3 | 23.08 |
| 50–56 Gy | 5 | 38.46 |
| Location | ||
| Cranial | 3 | 23.08 |
| Craniospinal | 3 | 23.08 |
| Total Body | 2 | 15.39 |
| Chemotherapy | 7 | 53.85 |
| Agents | ||
| Alkylating Agents | 7 | 53.85 |
| Anthracyclines | 4 | 30.77 |
| Vinca Alkaloids | 6 | 46.15 |
| Age at First Exposure | 8 | |
| <5 years | 6 | 46.15 |
| 6–10 years | 2 | 15.39 |
| Age at Last Exposure | 8 | |
| <5 years | 2 | 15.39 |
| 6–10 years | 4 | 30.76 |
| 11–15 years | 2 | 15.39 |
| Other Characteristics | ||
| Growth Hormone Deficiency | 4 | 30.77 |
ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem cell transplant; XRT, radiotherapy
Fig 1Change in endothelial function over the course of the study.
Baseline: n = 13, Following Regular Care: n = 13, Following Exercise, n = 13, *p < 0.05, **p < 0.01, °d > 0.5, d < -0.8.
Accelerometer, body composition and muscular strength and endurance data.
| Baseline | Following | Following | ||||||
|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | |||
| Accelerometer Data | ||||||||
| N | 13 | 9 | 10 | |||||
| Wear Time (min/day) | 842.60 | 21.63 | 752.34 | 10.74 | 767.54 | 18.32 | 0.003 | |
| Sedentary Breaks | 62.43 | 19.36 | 50.64 | 13.44 | 68.13 | 14.26 | 0.048 | |
| Counts (per min) | 164.92 | 121.38 | 109.72 | 53.01 | 147.37 | 46.39 | 0.222 | |
| Body Composition | ||||||||
| N | 13 | 13 | 13 | |||||
| Total Fat Mass (kg) | 23.76 | 15.16 | 24.56 | 14.93 | 23.23 | 15.75 | 0.559 | |
| Total Percent Fat (%) | 35.17 | 11.25 | 35.48 | 12.26 | 33.46 | 12.81 | 0.178 | |
| VAT Mass (g) | 594.44 | 742.96 | 626.44 | 615.47 | 397.91 | 260.20 | 0.316 | |
| VAT Volume (cm3) | 630.33 | 787.46 | 664.22 | 652.24 | 421.91 | 275.85 | 0.316 | |
| Total Lean Body Mass (kg) | 40.62 | 12.80 | 41.38 | 13.07 | 41.99 | 13.28 | 0.202 | |
| Muscular Strength (kg) | ||||||||
| N | 13 | 13 | 13 | |||||
| Latissimus Dorsi Pull Downs | 41 | 17 | 39 | 20 | 40 | 19 | 0.730 | |
| Bicep Curl | 7.5 | 2.5 | 8.0 | 3.0 | 9.0 | 3.5 | 0.009 | |
| Muscular Endurance (60 s) | ||||||||
| N | 13 | 13 | 13 | |||||
| Squats | 33 | 15 | 30 | 11 | 32 | 12 | 0.409 | |
| Sit-ups | 26 | 11 | 28 | 11 | 28 | 11 | 0.643 | |
| Push-ups | 23 | 12 | 21 | 10 | 27c | 14 | 0.180 | |
VAT, visceral adipose tissue
*Denotes statistical significance (p ≤ 0.05) between time points using One-Way Repeated Measures ANOVA
°Denotes statistical significance (p ≤ 0.05) between Baseline and Regular Care using post-hoc paired t-tests
†Denotes statistical significance (p ≤ 0.05) between Baseline and Exercise using post-hoc paired t-tests
ΔDenotes statistical significance (p ≤ 0.05) between Regular Care and Exercise using post-hoc paired t-tests
aDenotes moderate to large effect size (d = ≥ 0.5) between Baseline and Regular Care using Cohen’s D effect sizes
bDenotes moderate to large effect size (d = ≥ 0.5) between Baseline and Exercise using Cohen’s D effect sizes
cDenotes moderate to large effect size (d = ≥ 0.5) between Regular Care and Exercise using Cohen’s D effect sizes
Fig 2Percentage of time per day spent in different levels of physical activity.
Baseline: n = 13, Following Regular Care: n = 9, Following Exercise, n = 10, †d < -0.5, °d > 0.60.
Submaximal and maximal aerobic capacity data.
| Baseline | Following | Following | |||||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | ||
| Aerobic Capacity (3 min Stage) | |||||||
| N | 13 | 13 | 13 | ||||
| Rating Perceived Exertion | 8 | 2 | 8 | 2 | 7 | 1 | 0.252 |
| Submaximal HR (bpm) | 104 | 10 | 103 | 14 | 99 | 13 | 0.281 |
| Minute Ventilation (L·min-1) | 23.59 | 8.67 | 17.44 | 5.97 | 20.83 | 4.71 | 0.004 |
| Respiratory Exchange Ratio | 0.79 | 0.27 | 0.61 | 0.07 | 0.72 | 0.04 | 0.042 |
| VO2 (L·min-1) | 1.13 | 0.30 | 0.83 | 0.40 | 0.86 | 0.29 | 0.004 |
| VO2 (ml·kg-1·min-1) | 15.84 | 1.70 | 12.05 | 3.08 | 13.51 | 2.55 | 0.010 |
| Aerobic Capacity (6 min Stage) | |||||||
| N | 13 | 13 | 13 | ||||
| Rating Perceived Exertion | 9 | 2 | 9 | 2 | 8 | 2 | 0.025 |
| Submaximal HR (bpm) | 137 | 17 | 132 | 20 | 122 | 15 | 0.001 |
| Minute Ventilation (L·min-1) | 28.45 | 8.47 | 23.89 | 8.09 | 23.53 | 6.23 | 0.007 |
| Respiratory Exchange Ratio | 0.86 | 0.29 | 0.67 | 0.09 | 0.78 | 0.04 | 0.048 |
| VO2 (L·min-1) | 1.35 | 0.34 | 1.15 | 0.45 | 0.98 | 0.31 | 0.000 |
| VO2 (ml·kg-1·min-1) | 18.79 | 2.27 | 16.66 | 2.48 | 15.26 | 2.07 | 0.001 |
| Aerobic Capacity (9 min Stage) | |||||||
| N | 13 | 13 | 13 | ||||
| Rating Perceived Exertion | 11 | 2 | 10 | 2 | 9 | 2 | 0.142 |
| Submaximal HR (bpm) | 161 | 12 | 156 | 14 | 152 | 12 | 0.002 |
| Minute Ventilation (L·min-1) | 35.64 | 12.03 | 28.41 | 9.15 | 27.57 | 7.56 | 0.000 |
| Respiratory Exchange Ratio | 0.95 | 0.43 | 0.72 | 0.08 | 0.80 | 0.03 | 0.098 |
| VO2 (L·min-1) | 1.63 | 0.52 | 1.27 | 0.58 | 1.14 | 0.42 | 0.001 |
| VO2 (ml·kg-1·min-1) | 22.69 | 4.10 | 19.52 | 2.63 | 17.30 | 2.42 | 0.000 |
| Aerobic Capacity (Peak) | |||||||
| N | 13 | 13 | 13 | ||||
| Rating Perceived Exertion | 17 | 2 | 16 | 2 | 17 | 3 | 0.319 |
| Maximal Heart Rate (bpm) | 184 | 10 | 180 | 16 | 181 | 15 | 0.201 |
| Minute Ventilation (L·min-1) | 73.18 | 30.86 | 62.44 | 23.16 | 68.85 | 22.29 | 0.114 |
| Respiratory Exchange Ratio | 0.98 | 0.08 | 0.91 | 0.09 | 1.01 | 0.08 | 0.003 |
| VO2peak (L·min-1) | 2.72 | 1.03 | 2.46 | 1.10 | 2.51 | 1.14 | 0.163 |
| VO2peak (ml·kg-1·min-1) | 38.50 | 12.32 | 37.35 | 11.94 | 38.53 | 12.92 | 0.431 |
| VO2peak (ml·LBM-1·min-1) | 61.07 | 10.04 | 60.74 | 10.91 | 58.25 | 11.25 | 0.261 |
HR, heart rate; LBM, lean body mass.
*Denotes statistical significance (p ≤ 0.05) between time points using One-Way Repeated Measures ANOVA
°Denotes statistical significance (p ≤ 0.05) between Baseline and Regular Care using post-hoc paired t-tests
†Denotes statistical significance (p ≤ 0.05) between Baseline and Exercise using post-hoc paired t-tests
ΔDenotes statistical significance (p ≤ 0.05) between Regular Care and Exercise using post-hoc paired t-tests
aDenotes moderate to large effect size (d = ≥ 0.5) between Baseline and Regular Care using Cohen’s D effect sizes
bDenotes moderate to large effect size (d = ≥ 0.5) between Baseline and Exercise using Cohen’s D effect sizes
cDenotes moderate to large effect size (d = ≥ 0.5) between Regular Care and Exercise using Cohen’s D effect sizes